Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) Net Income towards Common Stockholders: 2024-2025

Historic Net Income towards Common Stockholders for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$74.1 million.

  • Kura Oncology's Net Income towards Common Stockholders fell 36.23% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$214.9 million, marking a year-over-year change of. This contributed to the annual value of -$174.0 million for FY2024, which is 13.99% down from last year.
  • As of Q3 2025, Kura Oncology's Net Income towards Common Stockholders stood at -$74.1 million, which was down 12.09% from -$66.1 million recorded in Q2 2025.
  • Kura Oncology's Net Income towards Common Stockholders' 5-year high stood at -$17.2 million during Q4 2024, with a 5-year trough of -$74.1 million in Q3 2025.
  • Moreover, its 2-year median value for Net Income towards Common Stockholders was -$54.4 million (2024), whereas its average is -$52.8 million.
  • Data for Kura Oncology's Net Income towards Common Stockholders shows a maximum YoY tumbled of 36.23% (in 2025) over the last 5 years.
  • Kura Oncology's Net Income towards Common Stockholders (Quarterly) stood at -$17.2 million in 2024, then plummeted by 36.23% to -$74.1 million in 2025.
  • Its last three reported values are -$74.1 million in Q3 2025, -$66.1 million for Q2 2025, and -$57.4 million during Q1 2025.